期刊文献+

顶空气相色谱法测定罗氟司特原料药中残留溶剂的含量 被引量:6

Determination of residual solvents in roflumilast by headspace gas chromatography
在线阅读 下载PDF
导出
摘要 采用顶空气相色谱法测定罗氟司特原料药中残留溶剂甲醇、丙酮、乙腈、二氯甲烷、乙酸乙酯、甲苯和N,N-二甲基甲酰胺的含量。在DB-624毛细管色谱柱(30 m×0.32 mm×1.80μm)上,以高纯氮气为载气,检测器为氢火焰离子化检测器,进样口温度为220℃,检测器温度为250℃,以程序升温方式使甲醇、丙酮、乙腈、二氯甲烷、乙酸乙酯、甲苯和N,N-二甲基甲酰胺达到了完全分离。结果表明,7种溶剂在对应于限度的50%~150%浓度范围内具有较好的线性关系(R2≥0.99),重复性RSD为1.8%~3.7%,平均回收率为94.9%~108.0%,检测灵敏度均达到了预定的分析要求,在罗氟司特原料药中仅检测出甲醇和丙酮。该方法简便灵敏、准确可靠,适用于罗氟司特原料药质量控制中的残留溶剂检查。 A method for determining the residual solvents in roflumilast by headspace gas chromatography was established.The determination was carried out on the DB-624 capillary column(30 m×0.32 mm×1.80 μm) with FID detector sequential increase of temperature programming.The carrier gas was nitrogen,the injector temperature was 220 ℃,and the detector temperature was 250 ℃ with sequential increase of temperature programming.The residual solvents methanol,acetone,acetonitrile,dichloromethane,ethyl acetate,toluene and N,N-dimethyl formamide were separated completely.The results showed that the correlation coefficients of linearity was more than 0.99% for the seven residual solvents within the concentration of 50% to 150% of relative individual limit specified,the RSD of repeatability ranged from 1.8% to 3.7%,the average accuracy ranged from 94.9% to 108.0%.And the sensitivity was complied with the predefined analytical requirements.Methanol and acetone were detected in roflumilast.The established method is simple and sensitive with accurate and reliable detection results,which could be used for the detection of residual solvents in roflumilast raw material drug.
作者 邱宣 王爱迪
出处 《应用化工》 CAS CSCD 2013年第8期1541-1543,共3页 Applied Chemical Industry
关键词 罗氟司特 残留溶剂 顶空气相色谱法 roflumilast residual solvent headspace gas chromatography
  • 相关文献

参考文献7

二级参考文献21

  • 1贺蓓.多中心随机对照临床研究表明Roflumilast可以改善慢性阻塞性肺病患者的肺功能[J].中华医学杂志,2005,85(36):2546-2546. 被引量:1
  • 2张玲.气相色谱法测定培美曲塞二钠中溶剂残留[J].中国药事,2006,20(7):412-413. 被引量:1
  • 3国家药典委员会编.《中国药典》2005年版.二部[s].附录残留溶剂测定法附录56-57.
  • 4RABE KF. Roflumilast for the treatment of chronic obstructive pulmonary disease [ J ]. Expert Rev Respir Med, 2010, 4 ( 5 ) : 543 -555.
  • 5RABE KF, HURD S, ANZUETO A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary [ J ]. Am Respir Crit Care Med, 2007,176 ( 6 ) : 532 - 555.
  • 6MANNINO DM, HOMA DM, AKINBAMI LJ, et al. Chronic ob- structive pulmonary disease surveillance: United States, 1971 - 2000[J]. MMWR CDC Surveill Summ, 2002, 51 (6) :1 - 16.
  • 7HATZELMANN A, MORCILLO EJ, LUNGARELLA G, et al. The preclinical pharmacology of roflumilast: a selective, oral phosphodiesterase inhibitor in development for chronic obstructive pulmonary disease[ J ]. Pulm Pharmacol Ther, 2010, 23 (4) : 235 -256.
  • 8PRESS NJ, BANNER KH. PDE4 inhibitors-a review of the current field[ J]. Prog Med Chem, 2009, 47 (1) :37 -74.
  • 9WOHLSEN A, HIRRLE A, TENOR H, et al. Effect of cyclic AMP elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices [ J ]. Eur J Pharmacol, 2010, 635 ( 1 - 3 ) : 177 - 183.
  • 10CHAPMAN RW, HOUSE A, JONES H, et al. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats [ J ]. Eur J Pharmacol, 2007, 571 (2 - 3) :215 -221.

共引文献39

同被引文献90

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部